Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Raises Price Target to $76
Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and raises the price target from $75 to $76.
BioXcel Therapeutics Q3 EPS $(1.49) Misses $(1.35) Estimate, Sales $137.00K Miss $1.09M Estimate
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(1.49) per share which missed the analyst consensus estimate of $(1.35) by 10.37 percent. This is a 55.21 percent decrease over losses of $(0.96) per share
HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $85
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $110 to $85.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Twitter Shares Surge Around 8%, Here’s 66 Biggest Movers From Yesterday
Gainers
Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.
Mizuho Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $19
Mizuho analyst Graig Suvannavejh initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $19.